Otsuka (OTCMKTS:OTSKY) Trading 9.1% Higher – Still a Buy?

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY)’s stock price shot up 9.1% during trading on Monday . The company traded as high as $35.94 and last traded at $35.94. 758 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 40,074 shares. The stock had previously closed at $32.94.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Otsuka from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Otsuka currently has a consensus rating of “Hold”.

Otsuka Price Performance

The firm’s 50-day moving average is $34.56 and its two-hundred day moving average is $32.79. The company has a market cap of $38.74 billion and a P/E ratio of 15.22. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67.

Otsuka (OTCMKTS:OTSKY) last released its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.43 by $0.16. Otsuka had a net margin of 15.01% and a return on equity of 12.33%. The business had revenue of $3.96 billion during the quarter, compared to analyst estimates of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Analysts anticipate that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 earnings per share for the current year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.